Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab and Apatinib in AFP-Producing Gastric Cancer
NCT04609176Phase 2Unknown
- Sponsor
- Peking University
- Start
- Nov 2020
- Primary completion
- Dec 2023
- Modality
- Small Molecules, Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Phase 2, open-label trial of camrelizumab and Rivoceranib in gastric cancer (GC) and gastroesophageal junction adenocarcinoma (2 arms), sponsored by Peking University. Primary endpoint: Objective Response Rate up to 24 months. Status: unknown.
02
Drugs
camrelizumabRivoceranib
03
Conditions
gastric cancer (GC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT04609176.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04609176.